Genetic Testing Significantly Alters Treatment Plans for chronic Kidney Disease Patients, study Finds
Table of Contents
Genetic testing is proving to be a powerful tool in the fight against chronic kidney disease (CKD), with a new study demonstrating substantial changes in patient management and prognosis estimations. The findings, released this week, underscore a growing movement toward incorporating genetic testing into standard CKD care, a practice increasingly supported by medical guidelines.
More than 800 million peopel worldwide are affected by CKD, placing a notable strain on global healthcare systems. The RenaCARE study, conducted by Fouad T. Chebib and colleagues, offers compelling evidence that a deeper understanding of a patient’s genetic makeup can dramatically improve outcomes.
RenaCARE Study Reveals Impact of Genetic Analysis
The RenaCARE (Renasight Clinical Application, Review, and Evaluation) study was a complete, single-arm inquiry involving 1,388 adult patients with CKD. Researchers utilized a 385-gene panel to identify potential genetic factors contributing to the disease in each participant, categorized across 13 pretest clinical groups. The study was designed to assess how this genetic information impacted clinical decision-making.
Investigators gathered detailed clinical histories before initiating testing. Follow-up questionnaires were administered to nephrologists at one month and again at one year post-testing, allowing researchers to track the evolving impact of the genetic insights. The one-year evaluation focused specifically on changes to CKD diagnosis and management strategies.
Nearly a Quarter of Patients Show Positive Genetic Findings
Results revealed a positive genetic finding in 24% of the patient cohort – a total of 335 individuals. Analysis of responses from 1,174 nephrologists,completed one year after testing,formed the core of the current report.
The nephrologists consistently reported the value of genetic testing in guiding clinical management. Notably, genetic testing prompted a change in treatment plans for a substantial 86% of patients who tested positive. Even among patients with negative test results, a significant 42% experienced alterations to their care.
Prognosis Estimates Shift Based on Genetic Insights
Beyond treatment adjustments, genetic testing also influenced physicians’ assessments of long-term patient outlook. A remarkable 55% of patients with positive genetic findings saw a change in their estimated five-year prognosis, as did 18% of those with negative results. This suggests that genetic information can refine risk stratification and inform more personalized care plans.
“Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD,” researchers concluded.
The study highlights the potential for genetic testing to move CKD care beyond traditional methods, offering a more precise and individualized approach to a widespread and costly disease.
Why, Who, What, and How did it end?
Why: The study aimed to determine the impact of genetic testing on the clinical management and prognosis of patients with chronic kidney disease (CKD).Researchers sought to understand if genetic information could improve treatment strategies and risk assessment.
Who: The study, known as RenaCARE, was conducted by Fouad T. Chebib and colleagues. It involved 1,388 adult patients with CKD and 1,174 nephrologists who provided follow-up data.
What: The RenaCARE study utilized a 385-gene panel to identify genetic factors in CKD patients. The research revealed that genetic testing significantly altered treatment plans for 86% of patients with positive results and 42% with negative results. Furthermore, prognosis estimates changed for 55% of those with positive findings and 18%
